Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has entered into a cooperation agreement with compatriot firm Allist Pharmaceuticals Co., Ltd (SHA: 688578). The alliance aims to study the combination of Abbisko’s investigational ABSK043 and Allist’s glecirasib in patients with KRAS-G12C mutant non-small cell lung cancer (NSCLC).
ABSK043: PD-L1 Inhibitor
ABSK043 is an in-house developed oral programmed-death ligand 1 (PD-L1) inhibitor with good oral bioavailability. Preclinical models have demonstrated anti-tumor efficacy comparable to approved PD-L1 antibodies. Phase I clinical studies for the drug in advanced solid tumors are currently underway in Australia and China.
Glecirasib: KRAS G12C Inhibitor
Glecirasib, developed by Allist Pharmaceuticals, is a KRAS G12C inhibitor undergoing multiple clinical studies in KRAS G12C mutant advanced solid tumors in China, the US, and Europe. Notably, it is being investigated as a monotherapy for pancreatic cancer, an indication that has earned the drug orphan drug designation and breakthrough therapy designation in the US and China, respectively.-Fineline Info & Tech
Leave a Reply